Qkine

Qkine is a biotechnology startup based in the United Kingdom, founded in 2016. The company specializes in manufacturing high-quality and novel growth factors for various applications including stem cell and organoid culture, regenerative medicine, and cellular agriculture. Qkine's products are aimed at supporting scientists in developing and scaling applications in these fields. The company also focuses on developing new growth factor technologies to cater to emerging fields such as cultured meat and 3D cell culture. Qkine's competitive edge lies in its proprietary technology developed in the laboratory of Dr. Marko Hyvönen, senior group leader at the University of Cambridge, which enables the manufacturing of highly pure bioactive recombinant proteins. Notably, the company sets a new benchmark for protein purity and utilizes protein engineering techniques to address biological and scalability challenges in the stem cell and regenerative medicine sector. This includes the development of optimized R-spondins to replace conditioned media for organoid culture. The company's commitment to quality is evident in its manufacturing process, conducted in a dedicated animal-derived component-free (ADCF) laboratory under an ISO 9001:2015 certification. Qkine also defines rigorous quality criteria, backed by detailed data and extensive quality testing on every lot to ensure reproducibility. The recent £4.30M Series B investment on 15 December 2022, led by Parkwalk Advisors, Downing Ventures, o2h Ventures, and Cambridge Angels group, speaks to the confidence that investors have in Qkine's potential to make a significant impact in the biotechnology and life sciences industries. For more information, visit www.qkine.com or contact the Qkine Team at [email protected].